1. P207 COVID-19: a prevalence rate two times lower than that of the general population in French patients with Inflammatory Bowel Disease treated with intravenous biologic agents. (21st January 2022) Authors: Lelong, M; Nancey, S; Bouguen, G; Allez, M; Serrero, M; Chupin, A; Caillo, L; Viennot, S; Blanc, P; Reimund, J M; Laharie, D; Olivier, R; Laurent, P B; Dib, N; De Maissin, A; Montuclard, C; Trang-Poisson, C; Gaillot, G; Bressollette-Bodin, C; Berthome, M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P404 Persistence of subcutaneous infliximab after switching from intravenous in a French national cohort of IBD patients in remission. (30th January 2023) Authors: Mathieu, N; Riviere, P; Heluwaert, F; Hébuterne, X; Chupin, A; Bouguen, G; Vuitton, L; Allez, M; Montuclard, C; Nachury, M; Nancey, S; Amélie, B; Gilletta, C; Abitbol, V; Altwegg, R; de Maissin, A; Plastaras, L; Ah Soune, P; Boureille, A; Bouhnik, Y Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i533 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗